Better High-Yield Dividend Stock: Pfizer or Novo Nordisk?
2026-10-04 21:15
•Reuben Gregg Brewer •The Motley Fool
••••• ••• Axe Cap view
Pfizer vs Novo Nordisk: Which High-Yield Dividend Stock Holds Up?
Despite higher yield, Novo Nordisk’s dividend safety is shakier compared to Pfizer’s broader portfolio and acquisition edge.
Both Pfizer and Novo Nordisk offer juicy dividend yields—6% and 4.7% respectively—but their dividend sustainability stories diverge sharply. Novo Nordisk’s strength used to be unmatched dominance in GLP-1 diabetes drugs. That’s now cracked, with Eli Lilly taking the lead thanks to a superior drug. Novo’s narrow focus and shift to volume-driven sales squeeze profit margins, while paying out over 110% of cash earnings to shareholders. That’s a red flag for dividend safety. Pfizer, meanwhile, faces its own challenges with patent cliff issues and a grinding R&D pipeline. However, its diversified drug portfolio and a track record of absorbing promising assets through acquisitions give it a buffer others lack. Its payout ratio is still high at 90%, so caution remains. South African investors tracking USD/ZAR should also watch Pfizer’s product mix benefit more from global stability than Novo’s niche risks. this is just our opinion and not financial advice
Trim Novo Nordisk exposure due to dividend risks and watch Pfizer for a more balanced yield play, but only with a cautious allocation given patent uncertainties.
- PFE
- NVO
- USD/ZAR
- Pfizer’s drug pipeline may fail to deliver new revenue
- Novo Nordisk could regain GLP-1 leadership or diversify successfully
6/10
Both Pfizer and Novo Nordisk face significant dividend safety concerns despite high yields. Novo Nordisk (4.7% yield) leads in GLP-1 drugs but has lost market share to Eli Lilly and lacks portfolio diversity, while Pfizer (6% yield) faces patent expirations and R&D challenges. However, Pfizer's broader product portfolio and acquisition strategy make it the relatively safer choice for dividend investors, despite both stocks carrying material risk.
Our take is based on reporting first published by The Motley Fool.